SCHEMBL23218399

SCHEMBL23218399

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2ccc(-c3ccnc(CN)c3)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
DPP4 P27487 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 4/20 0.36
PTGS2 P35354 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 6/20 0.35
MAPT P10636 5/20 0.35
ALDH1A1 P00352 4/20 0.35
HPGD P15428 3/20 0.35
GLA P06280 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
THRB P10828 1/20 0.33
FPR1 P21462 1/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852645 1.00 TSHR (0.41) TSHRDPP4MEN1KMT2AGAA
SCHEMBL23218812 0.91 CFD (0.39) GAAPTGS2SMN1; SMN2POLBKDM4E
SCHEMBL29591899 0.91 CFD (0.39) GAAPTGS2SMN1; SMN2POLBKDM4E
SCHEMBL29852964 0.87 TSHR (0.39) TSHRDPP4MEN1KMT2AGAA
SCHEMBL23218814 0.87 TSHR (0.39) TSHRDPP4MEN1KMT2AGAA
SCHEMBL23218533 0.86 CFD (0.43) TSHRDPP4MEN1KMT2AGAA
SCHEMBL29852791 0.86 CFD (0.43) TSHRDPP4MEN1KMT2AGAA
SCHEMBL23229167 0.86 MAPT (0.38) TSHRDPP4GAAPOLBKDM4E
SCHEMBL23218595 0.86 DPP4 (0.39) TSHRDPP4MEN1KMT2AGAA
SCHEMBL29852482 0.86 DPP4 (0.39) TSHRDPP4MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885DPP4 1386/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885DPP4 1004/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.